Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Customizable Embedded Real-Time Systems: Challenges and Key Techniques (CUSTOMER)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Computer science and informatics
Panel description: Informatics and information systems, computer science, scientific computing, intelligent systems
Countries involved: Sweden
Call: ERC Advanced Grant (ERC-2018-ADG, 2018)
Start date: 2019-10-01
End date: 2026-03-31
Duration (months): 78.0
Total project cost (EUR): 2499894.0
EU funding (EUR): 2499894.0
Participants: 1
Project status: SIGNED

Today, many industrial products are defined by software and therefore customizable: their functionalities implemented by software can be modified and extended by dynamic software updates on demand. This trend towards customizable products is rapidly expanding into all domains of IT, including Embedded Real-Time Systems (ERTS) deployed in Cyber-Physical Systems such as cars, medical devices etc. However, the current state-of-practice in safety-critical systems allows hardly any modifications once they are put in operation. The lack of techniques to preserve crucial safety conditions for customizable systems severely restricts the benefits of advances in software-defined systems engineering. CUSTOMER is to provide the missing paradigm and technology for building and updating ERTS after deployment – subject to stringent timing constraints, dynamic workloads, and limited resources on complex platforms. CUSTOMER explores research areas crossing two fields: Real-Time Computing and Formal Verification to develop the key techniques enabling (1) dynamic updates of ERTS in the field, (2) incremental updates over the products life time and (3) safe updates by verification to avoid updates that may compromise system safety. CUSTOMER will develop a unified model-based framework supported with tools for the design, modelling, verification, deployment and update of ERTS, aiming at advancing the research fields by establishing the missing scientific foundation for multiprocessor real-time computing and providing the next generation of design tools with significantly enhanced capability and scalability increased by orders of magnitude compared with state-of-the-art tools e.g. UPPAAL.

Keywords: real time systems,embedded systems,safety critical systems,scheduling,modelling and verification
Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055 (DO-IT)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative 2
Action type: Coordination and support actions
Partnership: IMI2 (Art-187)
Countries involved: Germany,Spain,Italy,Germany,Germany,Germany,Belgium,Hungary,Switzerland,Switzerland,Belgium,Belgium,Norway,Sweden,Sweden,France,France,France,United States,United Kingdom,United Kingdom,Denmark,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom
Call: COORDINATION AND SUPPORT ACTIONS (CSA) FOR THE BIG DATA FOR BETTER OUTCOMES PROGRAMME (H2020-JTI-IMI2-2015-07-two-stage, 2015)
Start date: 2017-02-01
End date: 2019-01-31
Duration (months): 24.0
Total project cost (EUR): 7191755.0
EU funding (EUR): 3549833.0
Participants: 36
Project status: CLOSED

The overall goal of the Big Data for Better Outcomes (BD4BO) programme is to facilitate the use of ‘big data’ to promote the development of value-based, outcomes-focused healthcare systems in Europe. To fully exploit the transformative potential of big data, consideration will need to be taken of the use of detailed personal and biological information across the spectrum of care delivery, starting from the development of innovative medicines and treatments, to market access and adoption, diffusion, and use in healthcare systems by providers and patients. This paradigm shift requires shared understanding and standards among healthcare stakeholders including patients, providers, payers, regulators, policy makers, pharmaceutical industry, and academia. OBJECTIVES The proposed Coordination and Support Action (CSA) will establish an enabling platform that brings together these stakeholder groups across the BD4BO programme to ensure quality and consistency of individual projects in line with the overarching programme objective. Our consortium therefore aims to promote the use of big Data for better Outcomes, policy Innovation and healthcare system Transformation (DO->IT). Accordingly, we will: • Define a programme strategy that ensures quality, consistency and sustainability of health outcomes related activities across individual BD4BO projects. • Integrate, synthesise, and manage knowledge from all BD4BO projects, making it easily accessible via a single knowledge exchange platform. • Act as pivotal point of collaboration, stakeholder engagement and communication for all BD4BO projects. • Provide transparency and enable the use of patient health data and human biological samples for research purposes by developing minimum data privacy standards for Informed Consent Forms (ICFs) and supporting materials for use by individual BD4BO disease-specific projects and more widely in the Research and Development (R&D) sector.

Keywords: big data outcomes real world evidence health policy data privacy informed consent
Disruptive On-line Stylist Engine (STILAVIA)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: SME instrument
Countries involved: Spain
Call: Open Disruptive Innovation Scheme (implemented through the SME instrument) (H2020-SMEINST-1-2015, 2015)
Start date: 2015-04-01
End date: 2015-09-30
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

STILAVIA is a new disruptive e-commerce platform that intends to provide on-line fashion shoppers with a totally new buying experience. Using our newly developed proprietary set of algorithms users will receive styling recommendations of specific clothing items based on their particular aspirations (to look thinner or taller; to emphasise breasts, shoulders, hips; to match the colour of clothing with the colour of the eyes or hair). This approach goes far beyond the usual on-line shopping procedure, which merely involves performing filtered searches in a previously selected retailer or offer aggregator, making the selection of the desired item based on pictures and written descriptions, and hoping that the size chosen will indeed fit. The consequence is that around 40% of purchases have some degree of dissatisfaction, either because the size was not correct or, mostly, because the piece of clothing does not meet the user expectations once worn. As a result 25% of the purchases are returned, with the retailer assuming the delivery expenses. The recommended items will be chosen among those on the databases provided by our strategic partners, major on-line retailers such as Zalando and Yoox, with whom we already signed B2B agreements. Our platform will help them to receive new costumers that will make satisfactory and definitive purchases, whereas we will receive a commission for each one of these transactions. In this SME Instrument Phase 1 we will launch a beta version of the platform in Spain (June 2015), and we will test it and improve it using the feedback of 300 users. In parallel, we will investigate the European market in order to adjust the algorithms to country-specific requirements, and with an eventual Phase 2 (which will include marketing activities) we will get ready for a global launch in 2017.

Keywords: ict challenges,entrepreneurship,beta testing,business plan
Artificial Intelligence for a new generation of Public Relations (PR): smart digital assistant for start-ups and SMEs to maximise results of press releases within the EU-28 and beyond (PRsuite)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Spain
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2018-12-01
End date: 2019-05-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Start-ups and SMEs are struggling to bring their message out into the market. Due to immediate and constant pressure to generate sales, these companies mostly focus their marketing activities in advertising as they don’t have the resources to sustainably implement Public Relations (PR). Press releases are an essential part of PR to inform about product launches, market achievements, news about the team, event promotions, etc, to regularly reach and build trust with current and potential customers by means of journalists, editors and influencers in all type of traditional and social media. It has been quantified that PR is x8 more effective that advertising, but in today’s massive mix of multi-channel and fragmented media world, the complexity has increased considerably for creating content together with well-segmented and timely distribution of press releases. Full-Service Providers (FSPs) act as one-stop-shop for the entire lifecycle of press releases but are prohibitively expensive for most SMEs, which must coordinate and manage several specialised tools to cover their needs. This problem significantly increases during the internationalisation of these companies when handling press releases in different languages. The technology developed by FSPs still relies on internal staff to service their clients, making the service expensive and not available 24/7. Our PRsuite is the only service that has automated the entire lifecycle of press releases. We are now incorporating Artificial Intelligence (AI) analysis for augmenting the capabilities of PR professionals to open a new generation of press releases. We are not competing against FSPs, but several of them are our distribution partners as we allow them to open and serve the largest customer segment: start-ups and SMEs. Reaching a market share of 0.51% of all the EU-28 SMEs already exporting to other countries inside the EU, we estimate €84.56m accumulated revenue, €48.96m accumulated profit and 85 new jobs created.

Keywords: marketing,public relations,press releases,communication,artificial intelligence,ai augmentation,big data,machine learning,traditional and social media,influencers,journalist,content
Microbial contribution to continental wetland carbon budget (MICADO)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: France
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2021-01-04
End date: 2023-01-03
Duration (months): 24.0
Total project cost (EUR): 196707.84
EU funding (EUR): 196707.84
Participants: 1
Project status: CLOSED

Continental wetlands are major carbon dioxide sinks but the second largest source of methane. Monitoring of wetland methane emissions revealed large inter-site variability that is hard to explain in the framework of current biogeochemical theories. Methane production in wetlands is an anaerobic microbial driven process involving a complex set of microbial metabolisms depending on the availability of (i) energy (via the presence of specific redox couples), (ii) organic substrates and (iii) specific microbial communities. To understand the complexity of microbial drivers on wetland methane emissions and quantify their contribution, the MICADO project will set up a multidisciplinary approach linking isotope organic geochemistry and environmental microbiology to assess microbial functioning in situ. As an organic geochemist I have developed an innovative approach to trace in situ microbial activity via compound specific carbon isotope analysis of microbe macromolecules and organic metabolites. The host institution is a leader in France in environmental microbiology and biogeochemistry developing high-throughput metagenomics and microbial rate assessments, for which I will be trained during the MICADO project. These techniques are highly complementary and combined they will provide a comprehensive knowledge on microbial metabolisms involved in organic matter degradation encompassing their complexity and interactions. This will revisit the relationships between organic substrate availability and microbial communities and will contribute at estimating the impact of microbial activity on wetland methane emissions. This project will give me the opportunity to acquire fundamental knowledge and to develop original lines of research that will consolidate my position as an independent scientist in biogeochemistry.

Keywords: isotope geochemistry,metagenomics
Imaging the proteome at the nanoscale (IMAGEOMICS)

Framework: Horizon 2020 — Excellent Science
Programme: Future and Emerging Technologies (FET)
Theme: EIC Pathfinder
Destination: Novel ideas for radically new technologies
Action type: Research and Innovation actions
Countries involved: Israel,Germany,Sweden
Call: FET-Open Challenging Current Thinking (H2020-FETOPEN-2018-2019-2020-01, 2020)
Start date: 2021-07-01
End date: 2024-12-31
Duration (months): 42.0
Total project cost (EUR): 3695981.25
EU funding (EUR): 3695981.25
Participants: 4
Project status: SIGNED

The key principle of biological imaging is specific labeling. The protein of interest is revealed by tagging with fluorophores, either by genetic encoding, using green-fluorescent-protein (GFP) variants, or by affinity labeling, using antibodies. This procedure has been successful for several decades, but has the great disadvantage that each protein needs to be tagged individually: specific antibodies are needed for each and every protein. This limitation stops imaging from becoming a high-throughput “omics” approach. We propose to change this here, through an imageomics approach based on a combination of probe development and nanoscale imaging. We will develop affinity probes that bind with high specificity not to specific proteins, but to amino acid sequences (peptides) that are present in more than one protein. We will choose 20-40 such peptides, in a fashion that ensures that virtually every protein in the human proteome contains a specific subset of the peptides. We will then develop nanobodies that bind to each of these peptides. We prefer nanobodies to antibodies, based on their small size and optimal penetration into biological samples. We will then use the nanobodies to label biological samples, and we will image them at the nanoscale, with a resolution that is sufficient to reveal single proteins. By applying the nanobodies in a combinatorial fashion, we will “read” the sequence of each protein in the preparation, which will result in an image of its whole proteome. We will start by applying this approach to 2-dimensional samples, such as fluids adsorbed to coverslips. This will lay the foundation for future diagnostic studies for a variety of human diseases, based on human fluids such as plasma or cerebrospinal fluid. In a later stage, we will proceed to analyze cells and tissues, by generating 3-dimensional proteomic images. This approach will make antibody-based imaging, blotting and diagnostics obsolete, and has therfore an immense potential.

Keywords: nanoscale,imaging,diagnostics,proteome,nanoprobes
NANOSTRUCTURED LARGE AREA PLASMONIC SYSTEMS DEPOSITED BY GAS FLOW SPUTTERING AND PLASMA-ENHANCED CVD PROCESSES (NanoLAPS)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Germany
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-04-01
End date: 2017-06-29
Duration (months): 24.0
Total project cost (EUR): 159460.8
EU funding (EUR): 159460.8
Participants: 1
Project status: CLOSED

Nanocomposites made of metallic nanoparticles (e.g. Au, Ag, Cu) embedded in a transparent matrix may display unique optical properties due to plasmonic effects resulting from the interaction of light with particles of nanometric size. This original behavior can be exploited in a wide range of applications including chemical and bio-sensors with extremely high sensitivity, spectroscopy, solar energy harvesting, and nanophotonics. In this context, Nano-LAPS project aims at the deposition of high purity nanocomposite materials with well controlled plasmonic absorption peak in the visible or infra-red ranges. Objectives are based on the encouraging results of preliminary work realized on this subject at FhG, which establishes a solid starting point for this project. The chosen approach is based on a unique and original deposition method combining gas flow sputtering and Plasma-Enhanced CVD processes. This technology allows coating large area substrates, with the highest purity, for a wide choice of nanoparticles (Au, Ag, Cu, Al, W, and high performance conductive oxides) and matrices (SiOxCy, TiOxCy, plasma polymers). The host organization senior researchers and management have an established reputation in research on thin films and nanotechnology, and are highly qualified to lead and to support this project, providing the best conditions for its success. Besides, the researcher has proved his capacity in leading and structuring scientific works on thin films coatings and process design. His experience will complement that of the host organization with new and original topics likely to draw scientific attention and open up perspectives for this research work.

Keywords: surface plasmon resonance,plasmonic coatings,nanocomposites,pecvd
EU-TOPIA: TOWARDS IMPROVED SCREENING FOR BREAST, CERVICAL AND COLORECTAL CANCER IN ALL OF EUROPE (EU-TOPIA)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Preventing disease
Action type: Research and Innovation actions
Countries involved: Italy,Estonia,Finland,Slovenia,Hungary,Netherlands,United Kingdom
Call: Evaluating existing screening and prevention programmes (H2020-PHC-2014-two-stage, 2014)
Start date: 2015-09-01
End date: 2020-08-31
Duration (months): 60.0
Total project cost (EUR): 2995683.0
EU funding (EUR): 2995683.0
Participants: 7
Project status: CLOSED

Breast, colorectal and cervical cancer cause 250,000 deaths each year, representing 20% of EU-cancer mortality. Although important progress has been made in both detection and treatment, there is persisting inequity in progress to reduce its burden. Screening programmes vary substantially between countries and in most long-term effectiveness of screening has not yet been assessed. The objective of EU-TOPIA is to systematically evaluate and quantify the harms and benefits of the running programmes for breast, cervical, and colorectal cancer in all European countries, and identify ways to improve health outcomes and equity for citizens. We will first identify significant inequities in screening outcomes by assessing the key set of quality indicators for benefits and harms in each country. Using these indicators, outcomes and cost-effectiveness of existing cancer screening programmes in 2015 will be estimated. For this, state-of-the-art models of the natural history of the cancers will be constructed, using country-specific data with and from country-specific experts. Barriers hindering implementation of optimal screening programs will be assessed, leading to road maps for improved screening. These road maps contain feasible changes, e.g., to extend or reduce the program, to change the screen test used or change key quality indicators, to perform activities that reduce screen-related harm or incorporate new developments in screening, and provide policymakers with evidence for increased, decreased or optimized use of screening. Capacity for self-evaluation of screening will be built using three web-based tools (monitoring, model-quantification and barrier assessment) explained and trained in workshops with country representatives, also from the Associated Countries. The project will lead to reduced inequity, reduced number of cancer deaths and over-diagnosed cases, and increase in life years gained and better cost-effectiveness by 2025. That is why we call it EU-TOPIA.

Keywords: cervical cancer,colorectal cancer,breast cancer,modelling,barriers,optimization
Alphaviral Immunotherapy against Glioblastoma (AVITAG)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Sweden
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2015, 2015)
Start date: 2016-05-01
End date: 2018-04-30
Duration (months): 24.0
Total project cost (EUR): 185857.2
EU funding (EUR): 185857.2
Participants: 1
Project status: CLOSED

Alphaviral Immunotherapy against Glioblastoma Glioblastomas (GBM) are the most frequent type of primary brain tumours with no treatment or cure available. Despite the current standard care, GBMs remain 100% fatal with median survival of patients for only 12 - 15 months. Thus, there is an urgent need for novel effective therapies. Among the emerging new therapeutic approaches is oncolytic virotherapy with replicative viruses that kill cancer cells. During his PhD studies, the applicant researcher, Miika Martikainen, has engineered novel tumour-targeted replicative alphavirus that shows promising therapeutic response in a syngeneic orthotropic mouse model for human GBM. As the next step, the applicant seeks to join Professor Magnus Essand’s group at the Uppsala University to conduct his postdoctoral research project that aims to development of clinically relevant oncolytic immunovirotherapy against GBM. To achieve this aim, previously unappreciated potency of Alphaviral oncolytic virotherapy is combined with synergistic immunotherapy with dendritic cell vaccination and/or adenoviruses. A detailed analysis of relevant immune responses associated with the therapy efficacy will be conducted to allow clinical translation of the results. The state-of-the-art methods available and the training received during the fellowship at host laboratory and secondments will arm the applicant with the skills and knowledge that allow him to establish a career as independent research scientist in a field that aims to develop novel ways to treat severe forms cancer.

Keywords: oncolytic virotherapy,immunotherapy,alphavirus,adenovirus,malignant glioma,dendritic cell vaccination